EPIDERMAL GROWTH FACTOR RECEPTOR 2;
EVEROLIMUS;
LAPATINIB;
MAMMALIAN TARGET OF RAPAMYCIN;
PHOSPHATASE;
PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR;
PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;
PROTEIN KINASE B BETA;
PROTEIN TYROSINE KINASE;
RAPAMYCIN DERIVATIVE;
SOMATOMEDIN C;
TRASTUZUMAB;
TRICIRIBINE;
ANTINEOPLASTIC ACTIVITY;
BIOINFORMATICS;
BREAST CANCER;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG POTENTIATION;
DRUG PROTEIN BINDING;
DRUG TARGETING;
EDITORIAL;
GENE AMPLIFICATION;
GENE MUTATION;
HIGH THROUGHPUT SCREENING;
HUMAN;
MORBIDITY;
MORTALITY;
PRIORITY JOURNAL;
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554-9.
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27.
Overexpression of P70S6 kinase protein is associated with increased risk of locoregional recurrence in nodenegative premenopausal early breast cancer patients
van der Hage JA, van den Broek LJ, Legrand C, et al. Overexpression of P70S6 kinase protein is associated with increased risk of locoregional recurrence in nodenegative premenopausal early breast cancer patients. Br J Cancer 2004;90:1543-50.
AKT2 is frequently up-regulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival
Bacus SS, Altomare DA, Lyass L, et al. AKT2 is frequently up-regulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene 2002;21:3532-40.
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93:1852-7.
Pre-clinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency
Lu CH, Wyszomierski SL, Tseng LM, et al. Pre-clinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency. Clin Cancer Res 2007;13:5883-8.
Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers
Xia W, Husain I, Liu L, et al. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 2007;67:1170-5.
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo
Momota H, Nerio E, Holland EC. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res 2005;65:7429-35.
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006;107:4053-62.
